Suspension of marketing authorization for Reductil and Sibutramin Teva

Users and patients are asked to note that:

• Sibutramine should no longer be prescribed with immediate effect.
• Sibutramine-containing medicinal products should no longer be dispensed.
• Patients are encouraged to contact their treating physician to discuss further action (however, patients who wish to discontinue therapy prior to seeing their physician may do so at any time).

More information:

European Medicines Agency

Inquiries:

E-mail:pr_pharmmed@ages.at

Further inquiry note

basg_anfragen@basg.gv.at